BioCardia Inc (BCDA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.08-0.92%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BCDA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -25.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
BCDA — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-08-21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On August 19, 2026, BioCardia, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market…
Why it matters: Earnings results show how well the company is doing. They also show progress in operations.
Watch forEarnings report shows smaller operating losses than in past quarters.
Also watch forEarnings report shows bigger operating losses than in past quarters.
Why it matters: Enrollment progress shows if the trial can succeed and get FDA approval.
Supportive ifEnrollment reaches at least 20 patients in the CardiAMP HF II trial by the end of Q3 2026.
Worry ifEnrollment stalls or drops below 10 patients by the end of Q3 2026.
Why it matters: Positive feedback could lead to a faster approval process for the Helix system.
Supportive ifFDA gives good feedback on the Helix submission by the end of Q3 2026.
Worry ifFDA has major concerns about the Helix submission or delays feedback.
Why it matters: Fixing compliance issues is important. It helps keep the company's listing and investor trust.
Supportive ifThe company gets confirmation that it meets Nasdaq listing rules.
Worry ifThe company gets more notices about not following the rules.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$330 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $718 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,603 loss on $10,000 · 66.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Partnerships could enhance BioCardia's market position and revenue potential. They are crucial for growth.
Supportive ifBioCardia announces a new partnership or licensing deal for Helix or Heart3D.
Worry ifNo new partnerships are made. Management says there are challenges in securing deals.
Why it matters: Fixing this issue is key for market trust. It also helps access to funds.
Worry ifBioCardia's stock price rises above $1.00 per share for 30 consecutive days.
Less concerning ifThe stock price stays below $1.00 for too long. This may lead to more delisting.
Why it matters: This approval could open treatment for 20,000 patients. It is a key regulatory milestone.
Supportive ifPMDA approval is granted for the treatment subgroup of 20,000 patients.
Worry ifPMDA denies approval or delays the decision past the expected date.
Why it matters: Approval would allow treatment for 20,000 patients. This is a key regulatory goal.
Supportive ifA public announcement will confirm PMDA approval for the treatment group.
Worry ifNo announcement or a delay in the PMDA approval process.
Why it matters: This submission is crucial for gaining approval in Japan. It targets a significant patient group.
Supportive ifBioCardia submits the CardiAMP Cell Therapy application to Japan's PMDA by the end of Q4 2026.
Worry ifThe submission is delayed past Q4 2026 or not completed.